Nebenwirkungen · Myocet liposomal (previously Myocet)
Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion. · Abschnitt 4.8 · PDF-Seite 8
HOS-091149 · Präparat HOS-084209
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-06T15:00:00Z · SHA-256 8f879c8b42a8f86dde725e12460699033047270c72b2613905f3d2414bc6cff4 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 5891–6246 im Abschnitt